Topoisomerase as target for antibacterial and anticancer drug discovery
- 1 March 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 28 (3), 419-435
- https://doi.org/10.3109/14756366.2012.658785
Abstract
DNA topoisomerases comprise a major aspect of basic cellular biology and are molecular targets for a variety of drugs like antibiotics, antibacterials and anticancer drugs. They act by inhibiting the topoisomerase molecule from relegating DNA strands after cleavage and convert the topoisomerases molecule into a DNA damaging agent. Though drugs of various categories acting through different mechanisms are available for the treatment, there are still problems associated with the currently available drugs. Therefore, Structural biologists, Structural chemists and Medicinal chemists all around the world have been identifying, designing, synthesizing and evaluating a variety of novel bioactive molecules targeting topoisomerase. This review summarizes types of topoisomerase and drug treating each class along with their structural requirement and activity. The emphasis has been laid in particular on the new potential heterocyles and the possible treatments as well as the current ongoing research status in the field of topoisomerase as dual targeting.Keywords
This publication has 87 references indexed in Scilit:
- 7-Azaindenoisoquinolines as Topoisomerase I Inhibitors and Potential Anticancer AgentsJournal of Medicinal Chemistry, 2011
- Targeting DNA topoisomerase II in cancer chemotherapyNature Reviews Cancer, 2009
- Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogueBMC Chemical Biology, 2009
- Topoisomerase II−Drug Interaction Domains: Identification of Substituents on Etoposide That Interact with the EnzymeBiochemistry, 2007
- Structural Studies of E. coli Topoisomerase III-DNA Complexes Reveal a Novel Type IA Topoisomerase-DNA Conformational IntermediateJournal of Molecular Biology, 2007
- New Peptide Inhibitors of Type IB Topoisomerases: Similarities and Differences Vis-a-vis Inhibitors of Tyrosine RecombinasesJournal of Molecular Biology, 2006
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- Antitopoisomerase drug action and resistanceEuropean Journal of Cancer, 1996
- MitoxantroneDrugs, 1991
- Mitoxantrone affects topoisomerase activities in human breast cancer cellsBiochemical and Biophysical Research Communications, 1986